Bupropion is contraindicated in bulimia because it dramatically increases the risk of seizures in people with the condition. This isn’t a theoretical concern. In a landmark clinical trial testing bupropion as a treatment for bulimia, 4 out of 55 patients experienced grand mal seizures, a rate far higher than anything seen in previous studies of the drug. That trial led to bupropion being pulled from the market entirely in 1986, and when it returned in 1989, it came back with a black-and-white rule: no use in patients with bulimia.
The Clinical Trial That Changed Everything
In the late 1980s, researchers ran a placebo-controlled, double-blind study to see if bupropion could reduce binge eating and purging in people with bulimia. The drug actually worked well for that purpose, significantly outperforming placebo. Side effects were generally minimal. But four participants in the bupropion group had grand mal seizures during treatment, and that changed the trajectory of the medication entirely.
A seizure rate of roughly 7% (4 out of 55) was alarming. In the general population taking bupropion at standard doses, the seizure risk sits around 0.1%. The researchers concluded that bupropion should not be given to bulimic patients, and the manufacturer voluntarily withdrew the drug from the market. When bupropion was reintroduced three years later with lower recommended doses, the FDA required the contraindication for bulimia to be printed on the label.
Why Bulimia Makes Seizures More Likely
Bupropion lowers the seizure threshold in a dose-dependent way, meaning it makes the brain more susceptible to seizures, and higher doses increase that susceptibility. In someone whose body is already under metabolic stress from bulimia, the combined effect can push the brain past its tipping point.
The purging cycle in bulimia causes electrolyte imbalances, particularly drops in potassium, magnesium, and sodium. These minerals play a direct role in how nerve cells fire. When levels are off, the brain’s electrical activity becomes less stable. Low magnesium and low blood sugar, both common in eating disorders, are independently recognized as seizure triggers. Research on seizures in eating disorder populations found that electrolyte abnormalities and low blood sugar accounted for about 10.7% of seizure cases, while malnutrition likely contributed to others through overlapping pathways.
On top of this, bupropion works by blocking the reabsorption of norepinephrine and dopamine, two brain chemicals that increase nervous system activity. The exact mechanism by which it provokes seizures is considered multifactorial and not fully understood, but the combination of a drug that lowers seizure threshold and a body already primed for electrical instability creates what the FDA calls “an unacceptably high risk.”
The Contraindication Covers All Eating Disorders
The FDA label doesn’t stop at bulimia. Bupropion is contraindicated in patients with a current or prior diagnosis of either bulimia or anorexia nervosa. The wording is notably broad: even a past diagnosis qualifies. This reflects the reality that metabolic disruptions from eating disorders can persist or recur, and that someone with a history of disordered eating may still carry elevated seizure risk factors like nutritional deficiencies or unstable eating patterns.
The contraindication applies to all formulations of bupropion, including the immediate-release, sustained-release (SR), and extended-release (XL) versions. While the newer formulations produce lower peak blood levels and were designed partly to reduce seizure risk in the general population, the FDA has not carved out an exception for eating disorder patients with any formulation.
What This Means for Treatment Options
If you have bulimia and need an antidepressant, or need medication to help manage binge-purge symptoms directly, the standard alternative is fluoxetine (Prozac). It’s the only antidepressant the FDA has specifically approved for treating bulimia. Fluoxetine is a selective serotonin reuptake inhibitor, which works through a completely different mechanism than bupropion and does not carry the same seizure risk. It can reduce binge eating and purging even in people who aren’t depressed, and tends to work best when combined with talk therapy, particularly cognitive behavioral therapy.
This matters because bupropion is widely prescribed for depression, smoking cessation, and sometimes off-label for weight management or attention difficulties. If you have a current or past eating disorder diagnosis, that history is important to share with any prescriber, since bupropion might otherwise seem like a natural choice for overlapping concerns. The contraindication isn’t a gray area or a soft warning. It’s one of the clearest lines in the drug’s labeling.